Haemodynamics in microvascular complications in type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue 4, 2002, Pages 286-304

  Candido, Riccardo ^a   Allen, Terri J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Diabetes mellitus; Haemo dynamics; Nephropathy; Neuropathy; Retinopathy

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILOSTAZOL; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; GROWTH FACTOR; IRBESARTAN; LISINOPRIL; N(G) NITROARGININE METHYL ESTER; NICERITROL; NITRIC OXIDE; PHOSPHORAMIDON; PROSTAGLANDIN E1 DERIVATIVE; PROSTAGLANDIN E2 DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SARPOGRELATE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD FLOW; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG MECHANISM; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; HEMODYNAMIC PROCESSES; HUMANS; MICROCIRCULATION;

EID: 0036657216     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.313     Document Type: Review

References (277)

1. Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000; 283: 3177-3179.
2. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350(Suppl. 1): SI9-SI13.
3. Clark CM Jr, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210-1217.
4. Cooper ME, Gilbert RE, Epstein M. Pathophysiology of diabetic nephropathy. Metabolism 1998; 47: 3-6.
5. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996; 25: 255-270.
6. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-1972.
7. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
8. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101: 527-537.
9. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
10. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-151.
11. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-438.
12. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1387-1407.
13. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A 1992; 89: 2873-2877.
14. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-243.
15. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403.
16. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37: 32-35.
17. Soulis T, Cooper ME, Sastra S, et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 1997; 40: 1141-1151.
18. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234.
19. Goldfarb S, Ziyadeh FN, Kern EF, Simmons DA. Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes 1991; 40: 465-471.
20. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46(Suppl. 2): S31-S37.
21. Pedersen MM, Christiansen JS, Mogensen CE. Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes 1991; 40: 527-531.
22. McAuliffe AV, Brooks BA, Fisher EJ, Molyneaux LM, Yue DK. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion. Nephron 1998; 80: 277-284.
23. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15: 1835-1843.
24. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev 2000; 16: 393-407.
25. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973-1988.
26. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000; 43: 1205-1223.
27. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997; 46(Suppl. 2): S104-S111.
28. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56: 393-405.
29. Seyer-Hansen K. Renal hypertrophy in streptozotocin-diabetic rats. Clin Sci Mol Med Suppl 1976; 51: 551-555.
30. Rasch R, Norgaard JO. Renal enlargement: comparative autoradiographic studies of 3H-thymidine uptake in diabetic and uninephrectomized rats. Diabetologia 1983; 25: 280-287.
31. Carraro M, Mancini W, Artero M, et al. Albumin permeability in isolated glomeruli in incipient experimental diabetes mellitus. Diabetologia 2000; 43: 235-241.
32. Fabris B, Candido R, Carraro M, et al. Modulation of incipient glomerular lesions in experimental diabetic nephropathy by hypotensive and subhypotensive dosages of an ACE inhibitor. Diabetes 2001; 50: 2619-2624.
33. Kanwar YS, Farquhar MG. Presence of heparan sulfate in the glomerular basement membrane. Proc Natl Acad Sci U S A 1979; 76: 1303-1307.
34. Jerums G, Allen TJ, Cooper ME. Triphasic changes in selectivity with increasing proteinuria in type 1 and type 2 diabetes. Diabet Med 1989, 6: 772-779.
35. Kofoed-Enevoldsen A. The Steno Hypothesis and glomerular basement membrane biochemistry in diabetic nephropathy. In The Kidney and Hypertension in Diabetes Mellitus (4th edn), Mogensen CE (ed.). Kluwer Academic: Boston, MA, 1998; 281-288.
36. Iozzo RV, Cohen IR, Grassel S, Murdoch AD. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 1994; 302: 625-639.
37. Tomlanovich S, Deen WM, Jones HW III, Schwartz HC, Myers BD. Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes 1987; 36: 556-65.
38. Friedman S, Jones HW III, Golbetz HV, Lee JA, Little HL, Myers BD. Mechanisms of proteinuria in diabetic nephropathy. II. A study of the size-selective glomerular filtration barrier. Diabetes 1983; 32(Suppl. 2): 40-46.
39. Remuzzi A, Perico N, Amuchastegui CS, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4: 40-49.
40. Scandling JD, Myers BD. Glomerular size-selectivity and microalbuminuria in early diabetic glomerular disease. Kidney Int 1992; 41: 840-846.
41. Lemley KV, Blouch K, Abdullah I, et al. Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 2000; 11: 2095-2105.
42. Fries JW, Sandstrom DJ, Meyer TW, Rennke HG. Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab Invest 1989; 60: 205-218.
43. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 1992; 42: 148-160.
44. Shankland SJ, Floege J, Thomas SE, et al. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 1997; 52: 404-413.
45. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
46. Mifsud SA, Allen TJ, Bertram JF, et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 878-882.
47. Johnson RJ. New insights into the pathogenesis of proteinuria. Am J Kidney Dis 2000; 36: 214-219.
48. Tryggvason K. Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 1999; 10: 2440-2445.
49. Furness PN, Hall LL, Shaw JA, Pringle JH. Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome. Nephrol Dial Transplant 1999; 14: 1234-1237.
50. Ahola H, Wang SX, Luimula P, Solin ML, Holzman LB, Holthofer H. Cloning and expression of the rat nephrin homolog. Am J Pathol 1999; 155: 907-913.
51. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44: 874-877.
52. Forbes JM, Bonnet F, Russo LM, et al. Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J Hypertens 2002; 20: 985-992.
53. Tucker BJ, Rasch R, Blantz RC. Glomerular filtration and tubular reabsorption of albumin in preproteinuric and proteinuric diabetic rats. J Clin Invest 1993; 92: 686-694.
54. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311: 89-93.
55. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219.
56. Hsueh WA, Anderson PW. Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. Am J Cardiol 1993; 72: 14H-21H.
57. Nosadini R, Fioretto P, Trevisan R, Crepaldi G. Insulin-dependent diabetes mellitus and hypertension. Diabetes Care 1991; 14: 210-219.
58. Kimmelsteil P, Wilson C. Intercapillary lesions in the glomeruli in the kidney. Am J Pathol 1936; 12: 83-97.
59. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed) 1987; 294: 1443-1447.
60. Deferrari G, Cheli V, Robaudo C. Treatment of diabetic nephropathy in its early stages. Diabetes Metab Rev 1997; 13: 51-61.
61. Cooper ME, Allen TJ, O'Brien RC, et al. Effects of genetic hypertension on diabetic nephropathy in the rat - functional and structural characteristics. J Hypertens 1988; 6: 1009-1016.
62. Cooper ME, Allen TJ, O'Brien RC, et al. Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. Diabetes 1990; 39: 1575-1579.
63. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
64. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380.
65. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 1985; 82: 5963-5967.
66. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 344: 541-544.
67. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 1998; 54: 343-352.
68. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, Wilkinson-Berka JL. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int 2000; 57: 1882-1894.
69. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G. Glomerular filtration rate in streptozocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy. Diabetes 1990; 39: 1182-1190.
70. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000; 77: S93-S98.
71. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-F486.
72. Kalinyak JE, Sechi LA, Griffin CA, et al. The renin-angiotensin system in streptozotocin-induced diabetes mellitus in the rat. J Am Soc Nephrol 1993; 4: 1337-1345.
73. Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL. Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int 1999; 56: 211-221.
74. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997; 29: 153-163.
75. Nagahama T, Hayashi K, Ozawa Y, Takenaka T, Saruta T. Role of protein kinase C in angiotensin II-induced constriction of renal microvessels. Kidney Int 2000; 57: 215-223.
76. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86: 1266-1272.
77. Levy J, Gavin JR III, Sowers JR. Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med 1994; 96: 260-273.
78. Okuda Y, Adrogue HJ, Nakajima T, et al. Increased production of PDGF by angiotensin and high glucose in human vascular endothelium. Life Sci 1996; 59: 1455-1461.
79. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997; 46: 1612-1618.
80. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
81. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci (Lond) 2001; 100: 591-599.
82. Wilkinson-Berka JL, Gibbs NJ, Cooper ME, Skinner SL, Kelly DJ. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant 2001; 16: 1343-1349.
83. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002; 25: 95-100.
84. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-2867.
85. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
86. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325-415.
87. Levin ER. Endothelins. N Engl J Med 1995; 333: 356-363.
88. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992; 13: 103-108.
89. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med 1999; 77: 364-376.
90. Seo B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89: 1203-1208.
91. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia 1999; 42: 1383-1394.
92. Yamauchi T, Ohnaka K, Takayanagi R, Umeda F, Nawata H. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 1990; 267: 16-18.
93. Chen S, Apostolova MD, Cherian MG, Chakrabarti S. Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells. Lab Invest 2000; 80: 1311-1321.
94. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, Wong NC. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 2000; 58: 1534-1545.
95. Fukui M, Nakamura T, Ebihara I, et al. Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 1993; 122: 149-156.
96. Cao Z, Cooper ME, Wu LL, et al. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension 2000; 36: 561-568.
97. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 1998; 47: 450-456.
98. Jandeleit-Dahm K, Allen TJ, Youssef S, Gilbert RE, Cooper ME. Is there a role for endothelin antagonists in diabetic renal disease? Diabetes Obes Metab 2000; 2: 15-24.
99. Johnston CI, Risvanis J, Naitoh M, Tikkanen I. Mechanism of progression of renal disease: current hemodynamic concepts. J Hypertens Suppl 1998; 16: S3-S7.
100. Burrell LM, Risvanis J, Johnston CI, Naitoh M, Balding LC. Vasopressin receptor antagonism - a therapeutic option in heart failure and hypertension. Exp Physiol 2000; 85: (Spec. No.): 259S-265S.
101. Johnston CI, Naitoh M, Risvanis J, Farina N, Burrell LM. New hormonal blockade strategies in cardiovascular disease. Scand Cardiovasc J Suppl 1998; 47: 61-66.
102. Burrell LM, Droogh J, Man in't Veld O, Rockell MD, Farina NK, Johnston CI. Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens 2000; 13: 1110-1116.
103. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001; 60: 715-721.
104. Tikkanen T, Tikkanen I, Rockell MD, et al. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 1998; 32: 778-785.
105. Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999; 353: 133-138.
106. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 1993; 43: 1306-1312.
107. Pieper GM. Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 1999; 42: 204-213.
108. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM. Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am J Physiol 1993; 265: F886-F895.
109. Komers R, Allen TJ, Cooper ME. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 1994; 43: 1190-1197.
110. Brownlee M. Lilly Lecture. 1993. Glycation and diabetic complications. Diabetes 1994; 43: 836-841.
111. Veelken R, Hilgers KF, Hartner A, Haas A, Bohmer KP, Sterzel RB. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 2000; 11: 71-79.
112. Sugimoto H, Shikata K, Matsuda M, et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998; 41: 1426-1434.
113. Thuraisingham RC, Nott CA, Dodd SM, Yaqoob MM. Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 2000; 57: 1968-1972.
114. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239.
115. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
116. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25: 913-917.
117. Gruden G, Thomas S, Burt D, et al. Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc Natl Acad Sci U S A 1997; 94: 12 112-12 116.
118. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791.
119. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
120. Wolf G, Ziyadeh FN, Zahner G, Stahl RA. Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. Kidney Int 1995; 48: 1818-1827.
121. Herman WH, Emancipator SN, Rhoten RL, Simonson MS. Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol 1998; 275: F8-F17.
122. Hirakata M, Kaname S, Chung UG, et al. Tyrosine kinase dependent expression of TGF-beta induced by stretch in mesangial cells. Kidney Int 1997; 51: 1028-1036.
123. Gruden G, Zonca S, Hayward A, et al. Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes 2000; 49: 655-661.
124. Riser BL, Cortes P, Yee J, et al. Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-beta. J Am Soc Nephrol 1998; 9: 827-836.
125. McMahon R, Murphy M, Clarkson M, et al. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-beta1. J Biol Chem 2000; 275: 9901-9904.
126. Lang F, Klingel K, Wagner CA, et al. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci U S A 2000; 97: 8157-8162.
127. Riser BL, Denichilo M, Cortes P, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11: 25-38.
128. Finckenberg P, Lassila M, Inkinen K, et al. Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet. Transplantation 2001; 71: 951-958.
129. Kuwabara T, Cogan DG. Retinal vascular patterns. VII. Acellular change. Invest Ophthalmol 1965; 4: 1049-1064.
130. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996; 97: 2883-2890.
131. Kern TS, Engerman RL. Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res 1994; 13: 863-867.
132. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993; 265: E783-E793.
133. Tilton RG, Chang K, Pugliese G, et al. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 1989; 38: 1258-1270.
134. Cringle SJ, Yu DY, Alder VA, Su EN. Retinal blood flow by hydrogen clearance polarography in the streptozotocin-induced diabetic rat. Invest Ophthalmol Vis Sci 1993; 34: 1716-1721.
135. Williamson JR, Chang K, Rowold E, et al. Sorbinil prevents diabetes-induced increases in vascular permeability but does not alter collagen cross-linking. Diabetes 1985; 34: 703-705.
136. Porta M. Endothelium: the main actor in the remodelling of the retinal microvasculature in diabetes. Diabetologia 1996; 39: 739-744.
137. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-1125.
138. Ceriello A, Dello Russo P, Zuccotti C, et al. Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation - a preliminary report. Thromb Haemost 1983; 50: 633-634.
139. Yu T, Mitchell P, Berry G, Li W, Wang JJ. Retinopathy in older persons without diabetes and its relationship to hypertension. Arch Ophthalmol 1998; 116: 83-89.
140. Klein R, Klein BE, Moss SE. The relation of systemic hypertension to changes in the retinal vasculature: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 1997; 95: 329-348.
141. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105: 1801-1815.
142. Zander E, Heinke P, Herfurth S, Reindel J, Ostermann FE, Kerner W. Relations between diabetic retinopathy and cardiovascular neuropathy - a cross-sectional study in IDDM and NIDDM patients. Exp Clin Endocrinol Diabetes 1997; 105: 319-326.
143. Group DD. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organization Multinational Study of Vascular Disease in Diabetics. Diabetologia 1985; 28(Suppl.): 615-640.
144. Agardh CD, Agardh E, Torffvit O. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Diabetes Res Clin Pract 1997; 35: 113-121.
145. Marshall G, Garg SK, Jackson WE, Holmes DL, Chase HP. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 1993; 100: 1133-1139.
146. Roy MS. Diabetic retinopathy in African Americans with type 1 diabetes: The New Jersey 725: II. Risk factors. Arch Ophthalmol 2000; 118: 105-115.
147. Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 1999; 77: 170-175.
148. McDonald HR, Schatz H. Grid photocoagulation for diffuse macular edema. Retina 1985; 5: 65-72.
149. Patz A, Fine SL. Diabetic macular edema. Int Ophthalmol Clin 1976; 16: 105-113.
150. Le Floch JP, Christin S, Bertherat J, Perlemuter L, Hazard J. Blood pressure and microvascular complications in type 1 (insulin dependent) diabetic patients without hypertension. Diabete Metab 1990; 16: 26-29.
151. Thai Multicenter Research Group on Diabetes Mellitus. Vascular complications in non-insulin dependent diabetics in Thailand. Diabetes Res Clin Pract 1994; 25: 61-69.
152. Bodansky HJ, Cudworth AG, Drury PL, Kohner EM. Risk factors associated with severe proliferative retinopathy in insulin-dependent diabetes mellitus. Diabetes Care 1982; 5: 97-100.
153. Mouton DP, Gill AJ. Prevalence of diabetic retinopathy and evaluation of risk factors. A review of 1,005 diabetic clinic patients. S Afr Med J 1988; 74: 399-402.
154. Lewis JM, Jovanovic-Peterson L, Ahmadizadeh I, Bevier W, Peterson CM, Williams B. The Santa Barbara County diabetic retinopathy screening feasibility study: significance of diabetes duration and systolic blood pressure. J Diabetes Complications 1994; 8: 51-54.
155. Dornan T, Mann JI, Turner R. Factors protective against retinopathy in insulin-dependent diabetics free of retinopathy for 30 years. Br Med J (Clin Res Ed) 1982; 285: 1073-1077.
156. Norgaard K, Feldt-Rasmussen B, Deckert T. Is hypertension a major independent risk factor for retinopathy in type 1 diabetes? Diabet Med 1991; 8: 334-337.
157. Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ. Prevalence of diabetic complications in relation to risk factors. Diabetes 1986; 35: 1332-1339.
158. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532.
159. Wan Nazaimoon WM, Letchuman R, Noraini N, et al. Systolic hypertension and duration of diabetes mellitus are important determinants of retinopathy and microalbuminuria in young diabetics. Diabetes Res Clin Pract 1999; 46: 213-221.
160. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520-526.
161. Chase HP, Garg SK, Jackson WE, et al. Blood pressure and retinopathy in type I diabetes. Ophthalmology 1990; 97: 155-159.
162. Muhlhauser I, Bender R, Bott U, et al. Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med 1996; 13: 536-543.
163. Chakrabarti S, Sima AA. Endothelin-1 and endothelin-3-like immunoreactivity in the eyes of diabetic and non-diabetic BB/W rats. Diabetes Res Clin Pract 1997; 37: 109-120.
164. MacCumber MW, Jampel HD, Snyder SH. Ocular effects of the endothelins. Abundant peptides in the eye. Arch Ophthalmol 1991; 109: 705-709.
165. Chakravarthy U, Douglas AJ, Bailie JR, McKibben B, Archer DB. Immunoreactive endothelin distribution in ocular tissues. Invest Ophthalmol Vis Sci 1994; 35: 2448-2454.
166. Chakrabarti S, Gan XT, Merry A, Karmazyn M, Sima AA. Augmented retinal endothelin-1, endothelin-3, endothelinA and endothelinB gene expression in chronic diabetes. Curr Eye Res 1998; 17: 301-307.
167. Takagi C, Bursell SE, Lin YW, et al. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci 1996; 37: 2504-2518.
168. Deng D, Evans T, Mukherjee K, Downey D, Chakrabarti S. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 1999; 42: 1228-1234.
169. Frank RN, Amin R, Kennedy A, Hohman TC. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol 1997; 115: 1036-1047.
170. Sone H, Kawakami Y, Okuda Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997; 40: 726-730.
171. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 1996; 74: 819-825.
172. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998; 47: 401-406.
173. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-1480.
174. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
175. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108: 2369-2379.
176. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997; 57: 765-772.
177. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998; 140: 947-959.
178. Dvorak HF, Nagy JA, Berse B, et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 1992; 667: 101-111.
179. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71.
180. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996; 114: 964-970.
181. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-1701.
182. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112: 1476-1482.
183. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72: 638-645.
184. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
185. Allen TJ, Cooper ME, Gilbert RE, Winikoff J, Skinni SL, Jerums G. Serum total renin is increased before microalbuminuria in diabetes. Kidney Int 1996; 50: 902-907.
186. Chaturvedi N. Modulation of the renin-angiotensin system and retinopathy. Heart 2000; 84(Suppl. 1): i29-i31, discussion i50.
187. Parving HH, Larsen M, Hommel E, Lund-Andersen H. Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 (insulin-dependent) diabetic patients with background retinopathy. Diabetologia 1989; 32: 440-444.
188. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
189. Sawicki PT. Lisinopril and albumin excretion in diabetes. Lancet 1997; 350: 662, discussion 663-664.
190. Stoschitzky K. Angiotensin II, VEGF, and diabetic retinopathy. Lancet 1998; 351: 836-837.
191. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994; 16: 383-391.
192. Pieper GM, Mei DA, Langenstroer P, O'Rourke ST. Bioassay of endothelium-derived relaxing factor in diabetic rat aorta. Am J Physiol 1992; 263: H676-H680.
193. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998; 47: 945-952.
194. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
195. Graier WF, Wascher TC, Lackner L, Toplak H, Krejs GJ, Kukovetz WR. Exposure to elevated D-glucose concentrations modulates vascular endothelial cell vasodilatory response. Diabetes 1993; 42: 1497-1505.
196. Langenstroer P, Pieper GM. Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol 1992; 263: H257-H265.
197. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-813.
198. Tesfamariam B, Brown ML, Cohen RA. Aldose reductase and myo-inositol in endothelial cell dysfunction caused by elevated glucose. J Pharmacol Exp Ther 1992; 263: 153-157.
199. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 1993; 21: 205-211.
200. Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 1998; 32: S54-S61.
201. Vanhoutte PM. Endothelin-1. A matter of life and breath. Nature 1994; 368: 693-694.
202. Rosen P, Ballhausen T, Bloch W, Addicks K. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia 1995; 38: 1157-1168.
203. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98: 2018-2026.
204. Pedram A, Razandi M, Hu RM, Levin ER. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997; 272: 17 097-17 103.
205. Matsuura A, Kawashima S, Yamochi W, et al. Vascular endothelial growth factor increases endothelin-converting enzyme expression in vascular endothelial cells. Biochem Biophys Res Commun 1997; 235: 713-716.
206. Lowe WL Jr, Florkiewicz RZ, Yorek MA, Spanheimer RG, Albrecht BN. Regulation of growth factor mRNA levels in the eyes of diabetic rats. Metabolism 1995; 44: 1038.
207. Sharp PS. The role of growth factors in the development of diabetic retinopathy. Metabolism 1995; 44: 72-75.
208. Fischer TA, Ungureanu-Longrois D, Singh K, et al. Regulation of bFGF expression and ANG II secretion in cardiac myocytes and microvascular endothelial cells. Am J Physiol 1997; 272: H958-H968.
209. Peifley KA, Winkles JA. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 242: 202-208.
210. Hasdai D, Holmes DR Jr, Richardson DM, Izhar U, Lerman A. Insulin and IGF-I attenuate the coronary vasoconstrictor effects of endothelin-1 but not of sarafotoxin 6c. Cardiovasc Res 1998; 39: 644-650.
211. Schini-Kerth VB. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. J Endocrinol Invest 1999; 22(5): 82-88.
212. Faure V, Courtois Y, Goureau O. Differential regulation of nitric oxide synthase-II mRNA by growth factors in rat, bovine, and human retinal pigmented epithelial cells. Ocul Immunol Inflamm 1999; 7: 27-34.
213. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985; 75: 1028-1036.
214. Ido Y, Vindigni A, Chang K, et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997; 277: 563-566.
215. Hu RM, Levin ER, Pedram A, Frank HJ. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993; 42: 351-358.
216. Lu M, Amano S, Miyamoto K, et al. Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci 1999; 40: 3281-3286.
217. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824.
218. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 [Author's translation]. Diabete Metab 1977; 3: 97-107.
219. Leedman PJ, Davis S, Harrison LC. Diabetic amyotrophy: reassessment of the clinical spectrum. Aust N Z J Med 1988; 18: 768-773.
220. Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR. The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later. Arch Neurol 1991; 48: 1130-1135.
221. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000; 43: 957-973.
222. Watkins PJ. Pain and diabetic neuropathy. Br Med J (Clin Res Ed) 1984; 288: 168-169.
223. Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 1996; 348: 1698-1701.
224. Andersen H, Nielsen JF, Poulsen PL, Mogensen CE, Jakobsen J. Motor pathway function in normoalbuminuric IDDM patients. Diabetologia 1995; 38: 1191-1196.
225. Rathmann W, Ziegler D, Jahnke M, Haastert B, Gries FA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993; 10: 820-824.
226. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 1995; 96: 1159-1163.
227. Low PA, Lagerlund TD, McManis PG. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol 1989; 31: 355-438.
228. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991; 261: E1-E8.
229. Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984; 107: 935-950.
230. Wright RA, Nukada H. Vascular and metabolic factors in the pathogenesis of experimental diabetic neuropathy in mature rats. Brain 1994; 117: 1395-1407.
231. Giannini C, Dyck PJ. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 1995; 37: 498-504.
232. Malik RA, Newrick PG, Sharma AK, et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989; 32: 92-102.
233. Britland ST, Young RJ, Sharma AK, Clarke BF. Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes 1990; 39: 909-913.
234. Yasuda H, Dyck PJ. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 1987; 37: 20-28.
235. Tesfaye S, Malik R, Harris N, et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996; 39: 329-335.
236. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997; 46: 665-670.
237. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1377-1384.
238. Reja A, Tesfaye S, Harris ND, Ward JD. Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med 1995; 12: 307-309.
239. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-1981.
240. Ishimura E, Nishizawa Y, Emoto M, et al. Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy. Nephron 1997; 76: 227-229.
241. Sasaki H, Schmelzer JD, Zollman PJ, Low PA. Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats. Acta Neuropathol (Berl) 1997; 93: 118-128.
242. Maxfield EK, Love A, Cotter MA, Cameron NE. Nerve function and regeneration in diabetic rats: effects of ZD-7155, an AT1 receptor antagonist. Am J Physiol 1995; 269: E530-E537.
243. Newrick PG, Wilson AJ, Jakubowski J, Boulton AJ, Ward JD. Sural nerve oxygen tension in diabetes. Br Med J (Clin Res Ed) 1986; 293: 1053-1054.
244. Ibrahim S, Harris ND, Radatz M, et al. A new minimally invasive technique to show nerve ischaemia in diabetic neuropathy. Diabetologia 1999; 42: 737-742.
245. Tesfaye S, Harris N, Jakubowski JJ, et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 1993; 36: 1266-1274.
246. Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994; 10: 189-224.
247. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995; 38: 1337-1344.
248. Arora S, Smakowski P, Frykberg RG, et al. Differences in foot and forearm skin microcirculation in diabetic patients with and without neuropathy. Diabetes Care 1998; 21: 1339-1344.
249. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 1998; 31: 1047-1060.
250. Kamata K, Miyata N, Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol 1989; 97: 614-618.
251. Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A. Alterations in endothelium-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats. Br J Pharmacol 1997; 121: 1383-1391.
252. Keegan A, Jack AM, Cotter MA, Cameron NE. Effects of aldose reductase inhibition on responses of the corpus cavernosum and mesenteric vascular bed of diabetic rats. J Cardiovasc Pharmacol 2000; 35: 606-613.
253. Kihara M, Low PA. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp Neurol 1995; 132: 180-185.
254. Ward KK, Low PA, Schmelzer JD, Zochodne DW. Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats. Brain 1989; 112: 197-208.
255. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994; 43: 1221-1228.
256. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994; 37: 449-459.
257. Takeda Y, Miyamori I, Yoneda T, Takeda R. Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats. Life Sci 1991; 48: 2553-2556.
258. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990; 33: 306-310.
259. Ikeda K, Wada Y, Sanematsu H, et al. Regulatory effect of experimental diabetes on the expression of endothelin receptor subtypes and their gene transcripts in the rat adrenal gland. J Endocrinol 2001; 168: 163-175.
260. McMillan DE, Utterback NG, La Puma J. Reduced erythrocyte deformability in diabetes. Diabetes 1978; 27: 895-901.
261. Wautier JL, Paton RC, Wautier MP, et al. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications. N Engl J Med 1981; 305: 237-242.
262. Simpson LO. Altered blood rheology in the pathogenesis of diabetic and other neuropathies. Muscle Nerve 1988; 11: 725-744.
263. Jude EB, Abbott CA, Young MJ, Anderson SG, Douglas JT, Boulton AJ. The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy. Diabetologia 1998; 41: 330-336.
264. Yasuda H, Sonobe M, Yamashita M, et al. Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235. Diabetes 1989; 38: 832-838.
265. Cotter MA, Dines KC, Cameron NE. Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 534-540.
266. Cameron NE, Cotter MA, Ferguson K, Robertson S, Radcliffe MA. Effects of chronic alpha-adrenergic receptor blockade on peripheral nerve conduction, hypoxic resistance, polyols, Na(+)-K(+)-ATPase activity, and vascular supply in STZ-D rats. Diabetes 1991; 40: 1652-1658.
267. Cotter MA, Cameron NE. Neuroprotective effects of carvedilol in diabetic rats: prevention of defective peripheral nerve perfusion and conduction velocity. Naunyn Schmiedebergs Arch Pharmacol 1995; 351: 630-635.
268. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12-18.
269. Maxfield EK, Cameron NE, Cotter MA, Dines KC. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia 1993; 36: 1230-1237.
270. Robertson S, Cameron NE, Cotter MA. The effect of the calcium antagonist nifedipine on peripheral nerve function in streptozotocin-diabetic rats. Diabetologia 1992; 35: 1113-1117.
271. Kappelle AC, Biessels G, Bravenboer B, et al. Beneficial effect of the Ca2+ antagonist, nimodipine, on existing diabetic neuropathy in the BB/Wor rat. Br J Pharmacol 1994; 111: 887-893.
272. Hotta N, Kakuta H, Fukasawa H, et al. Effect of niceritrol on streptozocin-induced diabetic neuropathy in rats. Diabetes 1992; 41: 587-591.
273. Kihara M, Schmelzer JD, Low PA. Effect of cilostazol on experimental diabetic neuropathy in the rat. Diabetologia 1995; 38: 914-918.
274. Shindo H, Tawata M, Aida K, Onaya T. Clinical efficacy of a stable prostacyclin analog, iloprost, in diabetic neuropathy. Prostaglandins 1991; 41: 85-96.
275. Cameron NE, Cotter MA. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia 1992; 35: 1011-1019.
276. Cameron NE, Dines KC, Cotter MA. The potential contribution of endothelin-1 to neurovascular abnormalities in streptozotocin-diabetic rats. Diabetologia 1994; 37: 1209-1215.
277. Cameron NE, Cotter MA. Effects of chronic treatment with a nitric oxide donor on nerve conduction abnormalities and endoneurial blood flow in streptozotocin-diabetic rats. Eur J Clin Invest 1995; 25: 19-24.